Meridian Bioscience Stock Forecast, Price & News

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Meridian Bioscience in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Meridian Bioscience stock.
View analyst ratings for Meridian Bioscience or view top-rated stocks.

Wall Street analysts have given Meridian Bioscience a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Meridian Bioscience wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Meridian Bioscience saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 3,870,000 shares, a decrease of 14.6% from the July 29th total of 4,530,000 shares. Based on an average daily trading volume, of 513,600 shares, the days-to-cover ratio is currently 7.5 days. Approximately 9.0% of the shares of the company are short sold.
View Meridian Bioscience's Short Interest.

Meridian Bioscience is scheduled to release its next quarterly earnings announcement on Friday, November 12th 2021.
View our earnings forecast for Meridian Bioscience.

Meridian Bioscience, Inc. (NASDAQ:VIVO) posted its quarterly earnings data on Thursday, August, 5th. The company reported $0.22 earnings per share for the quarter, missing the consensus estimate of $0.31 by $0.09. The business had revenue of $63.51 million for the quarter, compared to the consensus estimate of $73.12 million. Meridian Bioscience had a trailing twelve-month return on equity of 24.58% and a net margin of 23.29%.
View Meridian Bioscience's earnings history.

Meridian Bioscience's stock was trading at $6.43 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, VIVO shares have increased by 205.6% and is now trading at $19.65.
View which stocks have been most impacted by COVID-19.

Meridian Bioscience issued an update on its FY 2021 earnings guidance on Friday, September, 3rd. The company provided earnings per share (EPS) guidance of $1.610-$1.670 for the period, compared to the Thomson Reuters consensus estimate of $1.720. The company issued revenue guidance of $308 million-$314 million, compared to the consensus revenue estimate of $326.05 million.

2 brokers have issued twelve-month price objectives for Meridian Bioscience's shares. Their forecasts range from $27.00 to $34.00. On average, they expect Meridian Bioscience's share price to reach $30.50 in the next twelve months. This suggests a possible upside of 55.2% from the stock's current price.
View analysts' price targets for Meridian Bioscience or view top-rated stocks among Wall Street analysts.

7 employees have rated Meridian Bioscience CEO Jack Kenny on Glassdoor.com. Jack Kenny has an approval rating of 56% among Meridian Bioscience's employees. This puts Jack Kenny in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Meridian Bioscience include Align Technology (ALGN), West Pharmaceutical Services (WST), The Cooper Companies (COO), DENTSPLY SIRONA (XRAY), STAAR Surgical (STAA), Quidel (QDEL), ICU Medical (ICUI), Neogen (NEOG), Merit Medical Systems (MMSI), Haemonetics (HAE), Atrion (ATRI), Cerus (CERS), OraSure Technologies (OSUR), Antares Pharma (ATRS) and Anika Therapeutics (ANIK).
View all of VIVO's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Meridian Bioscience investors own include AbbVie (ABBV), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Pfizer (PFE), AT&T (T), Gilead Sciences (GILD), Amgen (AMGN), Alibaba Group (BABA) and Tesla (TSLA).

Meridian Bioscience trades on the NASDAQ under the ticker symbol "VIVO."

Meridian Bioscience's stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (17.11%), Vanguard Group Inc. (11.71%), Renaissance Technologies LLC (4.32%), Dimensional Fund Advisors LP (4.20%), State Street Corp (4.14%) and Fuller & Thaler Asset Management Inc. (3.91%). Company insiders that own Meridian Bioscience stock include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Felicia Williams, John Mccune Jr Rice, John Mcilwraith and John P Kenny.
View institutional ownership trends for Meridian Bioscience.

VIVO stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Goldman Sachs Group Inc., New York State Common Retirement Fund, Renaissance Technologies LLC, Prudential Financial Inc., M&G Investment Management Ltd., Wells Fargo & Company MN, and Parametric Portfolio Associates LLC. Company insiders that have sold Meridian Bioscience company stock in the last year include Bryan T Baldasare, John Mccune Jr Rice, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience or view top insider-selling stocks.

VIVO stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Fort Washington Investment Advisors Inc. OH, Kempen Capital Management N.V., Acuitas Investments LLC, State Street Corp, Systematic Financial Management LP, Millennium Management LLC, and Fuller & Thaler Asset Management Inc.. Company insiders that have bought Meridian Bioscience stock in the last two years include Anthony P Bihl III, Bryan T Baldasare, David Phillips, Felicia Williams, John Mcilwraith, and John P Kenny.
View insider buying and selling activity for Meridian Bioscience or or view top insider-buying stocks.

Shares of VIVO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of VIVO stock can currently be purchased for approximately $19.65.

Meridian Bioscience has a market capitalization of $851.91 million and generates $253.67 million in revenue each year. The company earns $46.19 million in net income (profit) each year or $1.07 on an earnings per share basis.

Meridian Bioscience employs 750 workers across the globe.

The following companies are subsidiares of Meridian Bioscience: Exalenz Bioscience.

Meridian Bioscience was founded in 1977.

The official website for Meridian Bioscience is www.meridianbioscience.com.

Meridian Bioscience is headquartered at 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244.

Meridian Bioscience's mailing address is 3471 RIVER HILLS DRIVE, CINCINNATI OH, 45244. The company can be reached via phone at (513) 271-3700 or via email at [email protected].